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Abstract
Background: T2DM is associated with atherogenic dyslipidemia (AD), defined as decreased HDL-C plus raised
triglycerides (TG). AD confers increased risk for CAD, even when LDL-C is at target. AD is rarely assessed due to lack
of screening methods consensus.
Aim: To establish the prevalence and severity of AD from log(TG)/HDL-C in T2DM males, and to determine how it
relates to cardiometabolic phenotype, glucose homeostasis, micro- and macrovascular complications, and 10-year
UKPDS CV risk.
Methods: 585 T2DM males divided according to quintiles (Q) of log(TG)/HDL-C. AD prevalence defined as HDL-C
<40 mg.dL
-1 plus TG ≥150 mg.dL
-1. b-cell function assessed with HOMA.
Results: Mean HDL-C and TG were 44 (13) and 204 (155) mg.dL
-1. AD prevalence was 35%. AD correlated with
lower b-cell function, with accelerated loss of insulin secretion, and with poorer HbA1c levels. AD was related to a
high prevalence of CAD, and also to 10-year absolute CAD risk.
Conclusions: log(TG)/HDL-C is a simple means to estimate AD and the residual CV risk it confers in T2DM. AD
closely associates with major cardiometabolic and glucose homeostasis determinants and poorer metabolic control.
The ratio also relates to macroangiopathy prevalence and ranks future CAD risk, and is well-suited to capture non-
LDL-related macrovascular residual risk and major glycemic determinants.
Introduction
Current guidelines recommend aggressive treatment of
low-density lipoprotein cholesterol (LDL-C) in patients
with type 2 diabetes mellitus (T2DM) with statins as
preferred agent [1]. Besides hypercholesterolemia,
T2DM is associated with a specific non-LDL dyslipide-
mia, known as atherogenic dyslipidemia (AD). The hall-
mark of AD consists of decreased high-density
lipoprotein cholesterol (HDL-C) together with raised tri-
glycerides (TG). AD is associated with insulin resistance
(IR), and confers a marked increase in residual vascular
risk, even when LDL-C is low [2-9].
Screening for AD may provide clinically relevant infor-
mation for assessing residual vascular risk associated
with the common determinants of low HDL-C and high
TG. However, this is rarely performed in practice, due
to lack of agreement criteria or consensual cut-offs to
routinely establish and grade AD based on measure-
ments of HDL-C and fasting TG levels. Low HDL-C
and high TG are part of the metabolic syndrome (MetS)
definition, either as single AD components or in combi-
nation. Cordero et al. proposed gender-specific ratio’s
thresholds to correlate with MetS in non-diabetics [10].
Yet, despite their usefulness for diagnosing MetS and
AD, low HDL-C and high TG are often dealt as sepa-
rate, second-rank modifiable CV risk factors [5,6,11,12].
A more comprehensive approach defines AD by the
combined occurrence of high TG levels and low HDL-C.
Yet, such seemingly easy estimation is hampered by
(i) lack of consensual cut-off values across gender, ethni-
cities and underlying conditions (ii)r e q u i r e m e n tf o r
baseline lipid values prior to lipid-lowering drugs (LLD),
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account imbalances between the severity of the two
non-LDL lipid abnormalities, underestimating the mag-
nitude of AD in groups with spontaneously low (Afro-
Americans, sub-Saharan Africans) or with elevated TG
levels prior to LLD or insulin [12-16].
Computing a ratio from fasting TG (numerator)a n d
fasting HDL-C (denominator) appears as such intuitively
more attractive than the combined occurrence to grade
AD severity. Prior log transformation of TG levels allows
for computing a broad range of TG values, as observed
in everyday practice, from normal levels in subjects
without AD to markedly hypertriglyceridemic states,
such as MetS and many T2DM patients. Assessing AD
with a log(TG)/HDL-C ratio also incorporates occur-
rence of mutually reinforcing or diverging confounders
affecting both fraction’s components, such as insulin-
sensitizers, certain LLDs, or ethanol intake (which often
increase both terms), or diet, exercise or menopausal
status, which affect numerator and denominator in
opposite directions [12,17-20].
The aim of the present study was to establish the pre-
valence, distribution and severity of AD from log(TG)/
HDL-C in a large cohort of T2DM males. We also deter-
mined whether the ratio provides predictive information
on cardiometabolic phenotype and glucose homeostasis
determinants. Finally, we analyzed the association
between AD and prevalence of micro- and macrovascular
complications, as well as its impact on 10-year CV risk
from the T2DM-specific United Kingdom Prospective
Diabetes Study (UKPDS) calculator [21-25].
Methods
The study design was cross-sectional and included 585
consecutive adult male outpatients with T2DM defined
according to the Expert Committee on the Diagnosis and
Classification of Diabetes Mellitus [26] and followed in a
single academic centre in Brussels (Belgium) between
January 2008 and June 2010. Exclusion criteria were
other forms of diabetes, severely impaired hepatic func-
tion, cancer, untreated thyroid conditions associated
with hypo- or hyperthyroidism, malignancies and malab-
sorptive gastro-intestinal disorders. The following vari-
ables were recorded: age, ethnicity, socio-educational
level, known diabetes duration, family history (cardiovas-
cular diseases, diabetes mellitus), self-reported leisure-
time (LT) weekly exertional exercise duration and daily
duration spent watching screen(s) such as television,
personal computer or visual numeric media, as surro-
gate for leisure-time sedentarity.
The presence of a metabolic syndrome (MetS score ≥3/
5) was defined according to AHA/NHLBI criteria [11,16].
The prevalence of AD was defined as the combination of
MetS criteria for low HDL-C at baseline (< 40 mg.dL
-1)
and high fasting TG at baseline (≥150 mg.dL
-1). The AD
ratio log(TG)/HDL-C computed log(fasting TG) to fasting
HDL-C. In patients treated with LLD(s), the TG and
HDL-C values were the last available ones prior to LLD
implementation. Normal values for log(TG)/HDL-C from
a control cohort of 80 lean subjects without diabetes or
family history for diabetes and untreated with LLD were:
0.036 (mean); 0.034 (median); 0.012 (SD); 0.014 (mini-
mum); 0.067 (maximum); 0.029 (percentile 25) and 0.042
(percentile 75).
As regards bioanthropometry, patients were measured
for body weight, height, body mass index (BMI), relative
and total body fat (BodyFat Analyzer, Omron BF 500),
waist circumference and conicity index (waist circumfer-
ence (m)/0.109 √[weight (kg)/height (m)]) [27-29].
Ultrasonographic evidence for fatty liver was considered
in the presence of hyperreflectivity and in the absence
of other etiological factors known to be associated with
liver steatosis, including excess ethanol intake.
Computer-based Homeostasis Model Assessment
(HOMA) of insulin sensitivity and beta-cell function
was previously detailed http://www.dtu.ox.ac.uk. Values
of HOMA B (%) were plotted as a function of HOMA S
(%), defining a hyperbolic product area (b × S) [unit: %
2;
normal value: 100%, corresponding to 10
4 %
2], which
represents the true, underlying b-cell function. (B × S)
loss over a subject’s lifetime span was obtained by divid-
ing 100-(B × S) by subjects’ age at the time of HOMA-
modeling, providing an estimate of annual (B × S) loss
rate (%.year
-1) [15,30-34].
Medications history inquired upon current use of oral
antidiabetic drugs, insulin, blood pressure (BP)-lowering
drugs, aspirin, and any LLD(s)). Hypertension history
was defined as systolic BP ≥140 mmHg and/or diastolic
BP ≥90 mmHg or current treatment with BP-lowering
drug(s) prescribed for treating high BP.
As regards macroangiopathy, coronary artery disease
(CAD) was retrospectively inferred from medical history
(myocardial infarction, angioplasty, stenting, revasculari-
zation surgery and/or significant coronary stenosis con-
firmed by angiography) and systematic review of all
procedures, screening (exercise testing, echocardiogra-
phy) or subclinical disease imaging data in the patient’s
records. Stroke was defined according to UK Prospective
Diabetes Study (UKPDS) criteria, i.e. any neurological
deficit lasting ≥1m o n t h ,n od i s t i n c t i o nb e i n gm a d e
between ischaemic, embolic and haemorrhagic strokes
[21]. In patients with multiple CV events, only the first
one was considered for prevalence. Peripheral artery dis-
ease (PAD) was defined by a well-documented medical
history of lower-limb(s) claudication and/or clinical or
imaging evidence for ischemic diabetic foot, angioplasty,
stenting, revascularization surgery and/or significant
lower-limb artery stenosis at Doppler ultrasonography
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diagnosed following dilated fundus examination, with
fluoangiography performed when deemed necessary by
an in-house ophthalmologist. The presence of a periph-
eral neuropathy was based on clinical examination (knee
and ankle reflexes, Semmes-Weinstein 5.07 monofila-
ment test) and/or 4-limbs electromyography.
The following biologic variables were assessed: gly-
cated haemoglobin (HbA1c), total cholesterol (C), HDL-
C, TG, LDL-C (from Friedewald’s formula), non-HDL-C
(by subtracting HDL-C from total C), apolipoproteins
(apo) A-I and B100 . As for non-lipid cardiometabolic
markers, levels of high-sensitivity C-reactive protein
(hsCRP), uric acid, cystatin C, fibrinogen, leucocytes
count, total and free testosterone, sex-hormone-binding
globulin (SHBG), ferritin, liver enzymes (aspartate ami-
notransferase [AST], alanine aminotransferase [ALT],
g-glutamyl transferase [gGT], homocysteine, folic acid
and vitamin B12 were determined. Normo, micro- and
macro-albuminuria were defined as urinary albumin
excretion <30 (normo-), 30-299 (microalbuminuria) and
≥300 μg.mg creatinine
-1 (macro-albuminuria) from first-
morning urine sample. Glomerular filtration rate was
estimated (eGFR) using the Modified Diet in Renal Dis-
ease (MDRD) formula [35].
The UKPDS Risk Engine provided 10-year absolute CV
risk estimates for T2DM individuals in primary CV pre-
vention related to coronary artery disease (CAD), lethal
CAD, stroke and lethal stroke, and was based on the 10
following variables: known T2DM duration, age, gender,
ethnicity, smoking status, chronic atrial fibrillation,
HbA1c level, systolic BP, total C and HDL-C [21-25].
Each patient gave informed consent, and the protocol
was approved by the local Institutional Review Board.
Statistical methods
Results are presented as means (± 1 standard deviation
(SD)) or proportions. The significance of differences
between means was assessed by one-way analysis of var-
iance for linear trend between means, and by a Chi-
squared test trend for differences in proportions. Results
were considered significant or non-significant (NS) for
p < or > 0.05, respectively.
Results
Patient’s characteristics are described in Table 1. There
were 585 male patients in the whole cohort, 89% of
whom of Caucasian ancestry. Diabetes duration was 14
(9) years. The prevalence of AD, defined as the combi-
nation of baseline HDL-C <40 mg.dL
-1 and TG ≥150
mg.dL
-1 was 35%. When patients were divided according
to AD quintiles of log(TG)/HDL-C, patients in the 1
st
AD quintile (Q I) had a mean log(TG)/HDL-C value
similar to that of control, non-diabetic subjects (see
Methods). T2DM patients from the 2
nd AD quintile
(Q II) had a mean log(TG)/HDL-C value corresponding
to the 75
th percentile of controls.
In the whole T2DM cohort, mean age (1 SD) was 65
(12) year, with a significant downward trend across AD
quintiles. Both smoking and ethanol intake showed sig-
nificant decreasing trends across quintiles. The propor-
tion of patients reporting LT physical activity and
screen-watching daily duration were significantly differ-
ent across quintiles, suggestive of both a marked
increase in sedentarity and a marked decrease in exer-
cise practice. There were highly-significant trends across
AD quintiles for progressively higher values of BMI,
waist circumference, conicity index, waist-to-height
ratio, fat mass and visceral fat. Liver steatosis was pre-
sent in 68% of the whole cohort, with significant rising
trends across quintiles, from 50% (Q I) to 83% (Q V)
(p < 0.0001). There was a stepwise increase across quin-
tiles of log(TG)/HDL-C in fasting insulinemia, from 80
to 132 pmol.l
-1 (p < 0.0001). Insulin sensitivity and the
hyperbolic product (B × S) were lower than the normal
value (100%) in the whole cohort, with a mean value of
53% (HOMA S) and 28.5% (B × S), respectively. There
were stepwise decreases across quintiles for both para-
meters, from 69% (HOMA S) and 35.7% (B × S) (Q I)
to 39% (HOMA S) and 22.5% (B × S) (Q V) (both p <
0.0001). The B × S loss rate also showed a highly-signifi-
cant trend toward worsening loss across AD quintiles,
from 1.15%.yr
-1 (Q I) to 1.44%.yr
-1 (Q V) (p < 0.0001;
Table 1).
Statin and fibrate were given to 54 and 21% of the
whole cohort, with a significant trend for increased
fibrate use across quintiles, from 9% (Q I) to 46% (Q V)
(p < 0.0001; Table 1). None of the patients were treated
with niacin. In the whole cohort, macroangiopathy was
present in 40%, as CAD (29%), TIA/stroke (9%) and/or
PAD (12%) (Table 1). There were significant trends for
higher prevalence of overall macroangiopathy, CAD and
TIA/stroke across AD quintiles, from 29% (overall), 15%
(CAD) and 5% (TIA/stroke) in Q I to 48% (overall), 33%
(CAD) and 13% (TIA/stroke) in Q V (p 0.060, 0.0097
and 0.0129, respectively). No trend was observed for
PAD across AD quintiles. After adjustment for inter-
quintile differences in age, overall macroangiopathy,
CAD and TIA/stroke prevalence increased even more
significantly across quintiles, from 28%, 15% and 6% (Q
I) to 52%, 36% and 14% (Q V), respectively (p 0.0010
(overall), 0.0024 (CAD), and 0.0126 (TIA/stroke)).
As regards glucose-lowering therapies, 59, 47, 7, 3,
and 42% were receiving metformin, a b-cell stimulant, a
glitazone, a DPP4-inhibitor and/or insulin, without rele-
vant trends between quintiles. Mean HbA1c in the
whole cohort was 7.53 (1.53)%, with 43% of patients at
HbA1c target (< 7.0%). There was a non-significant rise
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7.85% (Q V), and a significant decrease across AD quin-
tiles in proportion of patients reaching target HbA1c,
from 49% (Q I) to 35% (Q V; p 0.0155; Table 2).
The contribution of discrete components to the MetS
score for each AD quintile is depicted on Figure 1.
A MetS phenotype (score ≥3/5) was present in 76% in
the whole cohort. There was a highly-significant step-
wise rise in both MetS prevalence and score across AD
quintiles, from 36% and 2.3 (Q I) to 97% and 4.4 (Q V)
( b o t hp<0 . 0 0 0 1 ;T a b l e1a n dF i g u r e1 ) .T h e r ew e r en o
significant trends for higher prevalence of hypertension
or enlarged waist prevalence across quintiles. In the
whole cohort, hypertension prevalence was 86% and
mean systolo-diastolic blood pressure values were 139
(19) - 80 (11) mmHg, without trends across quintiles.
In the whole cohort, mean LDL-C was 98 (35) mg.dL
-
1,H D L - Cw a s4 4( 1 3 )m g . d L
-1, and current TG levels
were 171 (119) mg.dL
-1. Baseline, pre-LLD TG values
were 204 (155) mg.dL
-1.N o n - H D L - Cw a so na v e r a g e
131 (40) mg.dL
-1, and the delta between non-HDL-C
and LDL-C was 31 (18) mg.dL
-1, suggesting elevated
number of both apoB100-carrying particles and TG-rich
lipoproteins enrichment. There were significant trends
for decreasing values across AD quintiles for LDL-C,
apoA-I, and LDL-C/apoB100 ratio as surrogate for LDL
size (p 0.0047, < 0.0001, and < 0.0001, respectively).
There were significant trends as well for increasing
values across AD quintiles for non-HDL-C, non-HDL-C
minus LDL-C, and apoB100 (all p < 0.0001; Table 2).
As regards non-lipids markers, there were significant
trends for increasing levels across quintiles for hsCRP,
uric acid, cystatin C, leucocytes and ALT. Significant
decreases across quintiles were observed for SHBG and
vitamin B12 levels (p < 0.0001) (Table 2) as well as for
total testosterone (11.5 (4.4) [Q I], 11.2 (5.9) [Q II], 10.6
(4.1) [Q III], 9.7 (3.9) [Q IV] and 10.4 (4.9) nmol.L
-1 [Q
V] (p 0.0331)). Mean values for the non-lipid parameters
in the whole cohort were: fibrinogen 316 (76) mg.dL
-1,
ferritin 206 (189) ng.mL
-1,f r e et e s t o s t e r o n e0 . 1 9( 0 . 1 2 )
nmol.L
-1, homocysteine 14.1 (6.9) μmol.L
-1, folic acid
7.7 (5.2) ng.mL
-1, AST 26 (11) IU.L
-1,a n dgGT 43 (48)
IU.L
-1, with no trends across quintiles.
Diabetic retinopathy and peripheral polyneuropathy
were diagnosed in 22 and 30% of the whole cohort, with
no trend for higher prevalence across AD quintiles.
Table 1 Patients’ characteristics
All patients Q I Q II Q III Q IV Q V P
n 585 117 117 117 117 117
log(TG). HDL-C
-1 0.053 0.032 0.042 0.050 0.060 0.082 ~
age years 65 (12) 67 (12) 67 (12) 63 (12) 65 (12) 63 (10) 0.0083
smoking * % 36/64 41/59 44/56 40/60 31/69 24/76 0.0010
ethanol U.week
-1 16 (23) 21 (25) 19 (21) 16 (24) 14 (21) 11 (25) 0.0093
LT physical activity ** % 60/40 55/45 53/47 58/42 67/33 68/32 0.0072
LT screen watching *** hr.day
-1 3.1 (1.8) 2.7 (1.8) 2.8 (1.6) 2.8 (1.6) 3.0 (1.5) 4.0 (2.2) <0.0001
BMI kg.m
-2 28.8 (5.1) 26.5 (4.9) 27.9 (4.5) 29.2 (5.0) 30.1 (5.0) 30.4 (5.3) <0.0001
waist circumference cm 105 (13) 98 (13) 103 (11) 105 (12) 109 (12) 109 (13) <0.0001
conicity index m
2.kg
-1 1.35 (0.08) 1.33 (0.08) 1.35 (0.07) 1.36 (0.08) 1.37 (0.07) 1.37 (0.08) 0.0002
fat mass % 27.4 (6.2) 25.0 (6.7) 26.9 (6.0) 27.5 (6.5) 28.6 (5.5) 28.8 (5.6) <0.0001
visceral fat 0-3 0 14 (5) 12 (5) 13 (4) 14 (5) 15 (4) 15 (5) <0.0001
liver steatosis % 68 50 61 69 72 83 <0.0001
insulinaemia pmol.l
-1 113 (77) 80 (47) 103 (67) 122 (98) 125 (83) 132 (71) <0.0001
HOMA S % 53 (34) 69 (39) 61 (40) 50 (30) 49 (30) 39 (23) <0.0001
HOMA product (B × S) % 28.5 (18.2) 35.7 (21.6) 31.1 (16.2) 26.7 (15.8) 26.7 (16.2) 22.5 (16.5) <0.0001
(B × S) loss rate %.yr
-1 1.29 (0.45) 1.15 (0.50) 1.18 (0.33) 1.38 (0.52) 1.28 (0.40) 1.44 (0.39) <0.0001
metabolic syndrome % 76 36 67 83 95 97 <0.0001
metabolic syndrome score 1/5 to 5/5 3.4 2.3 2.9 3.5 4.0 4.4 <0.0001
statin/fibrate % 54/21 49/9 51/11 59/21 57/16 56/46 NS/<0.0001
macroangiopathy % 40 29 38 44 40 48 0.006
CAD % 29 15 32 32 31 33 0.0097
TIA/stroke % 9 5 5 1 01 01 3 0.0129
PAD % 12 15 13 11 8 14 NS
Results are expressed as means (1 SD) or proportions (%). *: never vs. former/current; **: no leisure-time (LT) physical activity (PA) vs. any level of LT-PA. CAD:
coronary artery disease; BMI: body mass index; HOMA B & S: beta-cell function and insulin sensitivity from homeostatic model assessment; PAD: peripheral artery
disease; Q: quintile; TIA: transient ischaemic attack. NS: not significant.
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adjustment for inter-quintile differences in mean age. In
the whole cohort, eGFR was 80 (27) ml.min
-1.1.73 m
2,
with a significant decrease across AD quintiles, from 85
(Q I) to 73 ml.min
-1.1.73 m
2 (Q V; p 0.0105). There
were significant increases across quintiles in mean albu-
minuria values and in albuminuria prevalence (both p <
0.0001; Table 2).
In the whole cohort, 331 patients were in primary CV
prevention, and therefore eligible for UKPDS risk esti-
mation. Their mean 10-year absolute CV risk prediction
was: 22 (16)% (CAD); 15 (14)% (fatal CAD); 14 (19)%
(stroke) and 2 (3)% (fatal stroke). Figure 2 depicts
UKPDS risk for CAD after adjustment for inter-quintile
differences in mean age. There were significant trends
for a markedly heightened risk across AD quintiles,
from 15% (CAD) and 10% (fatal CAD) in Q I up to 29%
(CAD) and 20% (fatal CAD) in Q V (p < 0.0001 and
0.0004). No such trends across quintiles were observed
for risk of stroke or lethal stroke (not illustrated).
Discussion
The main findings of the present study are fourfold.
Firstly, we observed a 35% prevalence of AD in T2DM
males. Secondly, the AD ratio log(TG)/HDL-C proved
an easy means to estimate IR, and was strongly asso-
ciated with IR and its cardiometabolic phenotype,
including fat distribution, liver steatosis and sedentarity
markers. Thirdly, the ratio was linked to a marked gra-
dient for residual risk of future CAD. Fourthly, the ratio
related to insulin secretion and b-cell function loss rate
in T2DM, and as such a higher ratio was associated
with non-attainment of target HbA1c. This AD ratio is
therefore exquisitely suited to assess both non-LDL resi-
dual vascular risk and glucose homeostasis determinants
in diabetic patients.
In the common form of T2DM, i.e. associated with
MetS and IR, the hallmark of AD is decreased HDL-C
level together with raised TG, while LDL-C is often only
marginally elevated. Further to these obvious non-LDL
abnormalities, there usually coexists an array of quanti-
tative and qualitative lipoproteins abnormalities, not evi-
denced from standard lipid assessment. These include
(i) a decrease in LDL size, often obscuring the absolute
increase in LDL particles number; (ii)a ni n c r e a s ei n
fasting and/or postprandial TG-rich apoB48 and/or
apoB100-carrying lipoproteins and their remnants; (iii)a
relative shift toward hepatic overproduction of apoCIII-
carrying VLDL and (iv) detrimental changes in HDL
quality and natural history (eg. lesser atheroprotective
Table 2 Laboratory values
All patients Q I Q II Q III Q IV Q V P
n 585 117 117 117 117 117
HbA1c % 7.53 (1.53) 7.32 (1.36) 7.41 (1.52) 7.48 (1.46) 7.60 (1.55) 7.85 (1.72) NS
HbA1c < 7.0% % 43 49 47 45 40 35 0.0155
cholesterol (C) mg.dl
-1 175 (41) 179 (35) 180 (37) 168 (40) 174 (41) 174 (48) NS
LDL-C mg.dl
-1 98 (35) 100 (32) 107 (34) 96 (34) 97 (34) 90 (38) 0.0047
non-HDL-C mg.dl
-1 131 (40) 118 (33) 132 (36) 127 (38) 136 (40) 143 (47) <0.0001
non-HDL-C - LDL-C mg.dl
-1 31 (18) 18 (8) 25 (11) 30 (15) 38 (18) 47 (21) <0.0001
HDL-C mg.dl
-1 44 (13) 61 (11) 48 (8) 42 (7) 38 (6) 32 (8) ~
apoA1 mg.dl
-1 143 (27) 167 (23) 151 (24) 139 (20) 137 (18) 122 (26) <0.0001
apoB100 mg.dl
-1 90 (26) 80 (23) 92 (26) 86 (24) 94 (25) 95 (30) <0.0001
pre-LLD TG mg.dl
-1 204 (155) 102 (46) 149 (61) 173 (82) 217 (72) 359 (254) ~
current TG mg.dl
-1 171 (119) 92 (40) 129 (66) 153 (77) 200 (102) 282 (165) ~
LDL-C. apoB100
-1 1.07 (0.28) 1.21 (0.24) 1.13 (0.26) 1.07 (0.26) 0.99 (0.28) 0.92 (0.27) <0.0001
hsCRP mg.dl
-1 0.36 (0.61) 0.36 (0.73) 0.20 (0.21) 0.42 (0.72) 0.35 (0.44) 0.48 (0.76) 0.0089
uric acid mg.dl
-1 5.7 (1.6) 5.5 (1.4) 5.7 (1.5) 5.6 (1.7) 6.3 (1.6) 5.7 (1.6) 0.001
cystatin C mg.l
-1 0.87 (0.34) 0.76 (0.21) 0.85 (0.22) 0.85 (0.27) 0.90 (0.38) 0.98 (0.48) <0.0001
white blood cells 10
3.mm
-3 7.20 (1.94) 6.63 (2.04) 6.70 (1.90) 7.49 (1.90) 7.57 (2.01) 7.56 (1.58) <0.0001
ALT IU.l
-1 32 (21) 27 (11) 33 (26) 30 (16) 38 (28) 32 (14) 0.0009
SHBG nmol.l
-1 37 (24) 46 (25) 37 (21) 31 (15) 36 (25) 34 (30) <0.0001
eGFR ml.min
-1.1.73 m
2 80 (27) 85 (25) 80 (23) 82 (29) 81 (24) 73 (30) 0.0105
albuminuria μg.mg creatinine
-1 100 (278) 50 (103) 30 (55) 108 (273) 106 (304) 201 (433) <0.0001
normal/(μ)albuminuria % 65/35 76/24 73/27 64/36 63/37 51/49 <0.0001
Results are expressed as means (1 SD) or proportions (%). ALT: alanine aminotransferase; apo: apolipoprotein; eGFR: estimated glomerular filtration rate; HDL:
high-density lipoprotein; hsCRP: high-sensitivity C-reactive protein; LDL: low-density lipoprotein; LLD: lipid-lowering drug(s); μ: micro-; Q: quintile; SHBG: sex
hormone-binding globulin; TG: triglycerides. NS: not significant.
Hermans et al. Cardiovascular Diabetology 2010, 9:88
http://www.cardiab.com/content/9/1/88
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decreased nascent HDL production) [2,5,12,13,36-39].
In the present study, current TG levels, non-HDL-C
levels, non-HDL-C minus LDL-C, and the ratio of LDL-C
to apoB100 confirm the high prevalence of AD-related
abnormalities in this mostly North-Caucasian population
of T2DM males. AD was also associated with high num-
ber of apoB100-carrying particles and with markers of
lipoprotein TG-enrichment [2,12,36,37]. Using consen-
sual MetS cutoffs for defining decreased HDL-C and ele-
vated TG [11,16], we observed a high prevalence of AD
in T2DM males, at more than one-third. AD is however
more likely to behave as a continuous CV risk variable.
This underlies the rationale to use the combined occur-
rence of low HDL-C and high TG as dichotomic variable
in order to assess AD prevalence in a population, while
the log(TG)/HDL-C appears more appropriate to rank
AD severity as a continuous variable in a given individual
[12]. This is confirmed from comparison with values
from control, non-diabetic subjects, showing that in
T 2 D M ,t h eA Dr a t i ow a sw e l la b o v en o r m a lv a l u e sf r o m
the third AD quintile onwards, hinting to the fact that
>60% within this population presents with some form of
AD. This was not unexpected, TG and HDL-C being
used to define the MetS phenotype, the latter being
highly-prevalent (76%) of this T2DM population.
Whereas the Atherogenic Index of Plasma (log(TG/HDL-
C) uses log transformation of the whole ratio, the present
study only applied log transformation to TG numerator, as
HDL-C range per se did not justify transformation. Skew-
ness from untransformed TG/HDL-C distribution fre-
quency was expected, with the TG term accounting for
most of it. Whereas skewness of HDL-C frequency distri-
bution was statistically significant, it was technically unim-
portant, and not surprisingly, HDL-C is rarely subject to
prior log transformation neither in routine clinical assess-
ment nor in clinical trials [12,17-20]. Dealing with a male-
only population offered the advantage of avoiding bimod-
ality in HDL-C and TG distributions due to gender differ-
ences (T2DM females exhibiting higher mean HDL-C and
lower TG values (by an average 6 and 12 mg/dl, respec-
tively; (data not shown)).
0
1
2
3
4
5
Q I Q II Q III Q IV Q V
M
e
t
S
 
s
c
o
r
e
hyperglycemia enlarged waist
high TG low HDL-C
HBP
Figure 1 Contribution of individual components of the metabolic syndrome (MetS) phenotype to the MetS cumulative score in 585
male patients with T2DM, divided into quintiles (n = 117; QI to QV) based on log(TG)/HDL-C ranking distribution. HBP: high blood
pressure; HDL-C: high-density lipoprotein cholesterol; TG: triglycerides.
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we used baseline TG and HDL-C values to compute the
ratio, prior to any anti-dyslipidemic drug(s), such as sta-
tins, fibrates or niacin, all of which being increasingly
used in combination therapy for T2DM. The difference
between baseline and current TG levels in this study
averaged 33 mg.dL
-1, supporting the rationale for such
an unyielding approach to obtain log(TG)/HDL-C. This
also allowed to establishing precisely the true, underly-
ing magnitude and frequency of AD in T2DM. Regard-
ing lifestyle-related confounders on AD prevalence, it is
noteworthy that both smoking and ethanol intake
showed significant decreasing trends across quintiles,
the inverse association with ethanol being expected, due
to its HDL-C-raising effects.
For non-lipid biochemistry the AD ratio was asso-
ciated, in a stepwise gradation, with a series of emerging
non-lipid cardiometabolic markers, all comorbid to
T2DM, such as fasting insulinemia, hsCRP, uric acid,
cystatin C, leucocytes count and glomerular filtration
rate. SHBG and total testosterone, but not free testoster-
one, significantly decreased in parallel across AD quin-
tiles, an expected finding since stepwise insulin
resistance is associated with decreased levels of the
androgen transporter [24,25,40-42].
IR develops in a conditional genetic or acquired envir-
onment associated with overall and central body fat,
sedentarity, and skeletal sarcopenia. This array of
metabolic abnormalities predisposes to CV risk, and is
easily captured clinically by (i) the presence of a MetS
phenotype and (ii) by the incremental MetS score
[11,12,16,43,44]. Numerous abnormalities defining AD
are associated, causally or as markers, with IR and its
compensatory portal hyperinsulinemia, and with liver
steatosis, the upstream organ responsible of excess
VLDL synthesis and export [12]. The present results
show that log(TG)/HDL-C is an easy means to rank
T2DM patients alongside IR, liver steatosis, leisure-time
sedentarity (with screen-watching as surrogate), lack of
leisure-time physical activity, and MetS score. This
extends previous findings showing that this ratio was a
surrogate for IR in healthy African Americans and white
Caucasians [45]. In our study, log(TG)/HDL-C also asso-
ciated with both prevalent CAD, prevalent stroke but
neither prevalent eye or nerve microangiopathy, nor
stroke risk, nor prevalent PAD, the two latter caused by
a combination of micro- and macrovascular end-organ
damage. On the other end, albuminuria prevalence or
level, both markers of mixed micro/macrovascular end-
organ damage in T2DM, were significantly associated
with AD.
In the ACCORD Lipid trial, impacting upon AD using
a simvastatin-fenofibrate combination therapy reduced
macrovascular risk in a subset patients with AD defined
by concurrent HDL-C <1
st tertile plus TG >3
rd tertile of
baseline cohort lipids. This was in line with previous
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Figure 2 UKPDS Risk Engine 10-year absolute predicted risk of developing non-fatal or fatal coronary artery disease (CAD; grey bars)
or fatal CAD (solid bars) in 331 T2DM males according to quintiles of log(TG)/HDL-C ranking distribution. Within each quintile, data were
obtained from subsets of patients in primary cardiovascular prevention: QI: n = 83; QII: n = 59; QIII: n = 65; QIV: n = 65; and QV: n = 59. HDL-C:
high-density lipoprotein cholesterol; TG: triglycerides. Significance of differences between quintiles: P < 0.0001 (CAD) and P = 0.0004 (fatal CAD).
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in post-hoc subgroup analyses from landmark fibrate
trials [12,13,44,46-48]. By contrast, in the ACCORD
Lipid Eye substudy, microvascular risk of retinopathy
progression was markedly reduced by combination sim-
vastatin-fenofibrate therapy in a broader range of base-
line non-LDL lipids [49]. Besides fibrates, another
promising pharmaceutical means to improve the AD
ratio is to raise HDL-C levels with niacin or cholesteryl
ester transfer protein inhibitors [5]. Parallel to pharma-
ceutical reinforcement, therapeutic lifestyle intervention
emphasizing on a diet low in carbohydrates and ethanol,
on caloric restriction and expenditure through exercise
should not be overlooked as a means to improve the
AD ratio, which in this study was clearly associated with
sedentarity and lack of leisure-time exercise.
The AD ratio was also linked with more severe impair-
ment in endogenous insulin secretion, as well as worsen-
ing of hyperbolic product (B × S) loss, heralding earlier
and more intensive requirement for stepping-up of glu-
cose-lowering therapies, including insulin [14,15,30,34,50].
This unexpected finding is all the more relevant, as the
ratio simultaneously associates with more severe IR and
faster insulin secretory loss. Such a detrimental combina-
tion is poised to lead to poorer glycemic control. This
association between log(TG)/HDL-C and b-cell impair-
ment does not simply reflect decreased insulin output due
to b-cell loss, as the latter would bring about opposing
effects on the ratio terms, with reduced liver TG synthesis
and VLDL export (portal hypoinsulinemia) and reduced
lipolysis of TG-rich particles (systemic hypoinsulinemia).
In addition, systemic TG removal from VLDL may also be
altered as a result of decreased insulin sensitivity affecting
lipoprotein lipase [12]. Regarding glycemic control, T2DM
patients with elevated raised AD ratio qualify for more
proactive approaches to control hyperglycemia with insu-
lin-sensitizers and/or insulin replacement therapy.
This study has several limitations. Firstly, we analyzed
only male patients. Secondly, the cross-sectional design
does not allow establishing causality relationships.
Third, incorporation of routine measurement of HDL-C
as denominator does not allow distinguishing dysfunc-
tional, less atheroprotective or even atherogenic HDL
subclasses which may be more prevalent in patients
with T2DM. Besides compositional changes in HDL
induced by overproduction of TG-rich lipoproteins [12],
loss of functionality may also result from oxidative
changes in predisposed individuals, such as those with
haptoglobin 2-2 genotype, not captured from simple
measurement of HDL-C level [51]. Nevertheless, dys-
functional subclasses often coexist alongside decreased
HDL-C, so that a low HDL-C level in the ratio may
reflect to some extent underlying qualitative defects
[52]. Finally, the population under study was mostly of
European Caucasian ancestry. The conclusions need to
be confirmed in other major racial/ethnic diabetic and
nondiabetic subgroups. The validity of the TG/HDL-C
ratio as a simple, clinically useful estimator of IR was
reported by Li et al. across race/ethnic subgroups in a
large, nationwide sample of nondiabetic subjects from
three major US populations (non-Hispanic whites,
blacks and Mexican Americans) [53].
B a s e do nt h ep r e s e n tr e s u l t s ,w ec o n s i d e rlog(TG)/
HDL-C as a simple means to estimate AD, and the resi-
dual vascular risk it confers, in fully-treated T2DM male
patients. In addition, AD closely associates with the two
major determinants of glucose homeostasis, affecting the
natural history of hyperglycemia and its metabolic con-
trol. In patients in primary CV prevention, this AD ratio
also yielded a marked, stepwise increase, in 10-year CV
risk for CAD and fatal CAD. Using the log(TG)/HDL-C
therefore adds a wealth of pertinent information on resi-
dual macrovascular risk, beyond that provided by indivi-
dual components of the available lipid profile. In T2DM,
this AD ratio is a simple means to assess both non-LDL-
related residual vascular risk and glucose homeostasis.
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